Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 in Poorly Controlled Asthma
NCT02127697Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing NVA237 with Placebo (2 arms). Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 26 weeks. Planned start Mar 2015; status: withdrawn.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02127697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127697.